Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 31Terminated 10Recruiting 6Withdrawn 5Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Gynecologic 2Breast 2Thoracic 1Sarcoma 1Genitourinary 1

Conditions

Colorectal Neoplasms 16Glioblastoma 8Ovarian Neoplasms 7Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Pancreatic Neoplasms 5Rectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Neoplasms 2Melanoma 2Liver Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Rectal Cancer Patients 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Peritoneal Neoplasms 1Optic Nerve Diseases 1

Interventions

Gemcitabine 27Taxes 9Capecitabine 8Albumin-Bound Paclitaxel 6pembrolizumab 5Radiosurgery 5Oxaliplatin 5Bevacizumab 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Specimen Handling 4Secretin 4Fluorouracil 4Drug Therapy 4Ascorbic Acid 4durvalumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Cyclophosphamide 3Cisplatin 3Biopsy 3palbociclib 2methylnaltrexone 2folfirinox 2fludarabine 2entinostat 2aldesleukin 2Trastuzumab 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Pancreatic Neoplasms × Bevacizumab × Clear all
NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

ImmunityBio, Inc.

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05431582 2023-06-15

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Withdrawn
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT00253526 2015-04-28

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT00524069 2013-02-01

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Roswell Park Cancer Institute

Phase NA Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡